Consonance Capital

Civic Eagle, Inc. is a software company that provides a workflow solution for advocates and policy teams, enabling them to discover, analyze, and manage state and federal legislation. Founded in 2015 and based in Minnesota, Civic Eagle offers a platform called Enview that consolidates legislative information and team communications, allowing lobbyists and policy professionals to streamline their efforts without manual data entry. The platform helps users track and engage with legislation across the country, empowering policy advocates to focus on their campaigns and promote more effective democratic outcomes for their communities.

Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to repair damaged tissues and improve organ function. The company utilizes antibody platforms that act as Wnt and R-spondin mimetics to stimulate tissue regeneration in a variety of organs. Its key programs include SZN-043, which aims to promote hepatocyte regeneration in liver diseases, and SZN-1326, designed to repair diseased epithelial tissue for patients with inflammatory bowel disease. Surrozen's research targets several disease areas, including conditions affecting the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system, by engaging the body’s natural biological repair mechanisms. The company was incorporated in 2015 and continues to advance its innovative therapeutic approaches.

Rivy is making it easier to finance small and medium sized businesses in Africa. There is a need for financing of $158 bn for SMEs in Nigeria alone. To start, Rivy o helps SMEs access and spend lender capital effectively. During their first full operational year in 2020, the Rivy o co--founders leveraged their domain expertise and founding experience to beat their 2020 goal by 50%.

Silence Therapeutics plc is a biotechnology company based in London, specializing in the discovery and development of innovative RNA therapeutics. The company focuses on utilizing short interfering RNA (siRNA) technology to modulate gene expression and address various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. Its pipeline includes several product candidates, such as SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to reduce the risk of cardiovascular diseases. Silence Therapeutics has established strategic collaborations with major organizations, including AstraZeneca, to advance the development of siRNA therapeutics across multiple disease areas. The company leverages its proprietary genetic toolkit and delivery systems to optimize therapeutic outcomes, harnessing the body's natural biological mechanisms for effective treatment.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Orsini Healthcare manages the handling and service requirements of pharmaceuticals including dispensing, distribution, reimbursement, case management, and other services to patients with chronic diseases. They help patients, doctors, insurance companies, and manufacturers improve care, processes, and outcomes.

Psychiatric Medical Care, LLC is a Nashville-based company founded in 2003 that specializes in behavioral health management services, particularly for the geriatric population. The company offers a range of solutions, including telepsychiatry, intensive outpatient programs, and adult inpatient units, aimed at treating mental health conditions such as depression, anxiety, mood disorders, and post-traumatic stress disorder. In addition to direct patient care, Psychiatric Medical Care supports hospitals and healthcare partners by providing recruitment, training, and education for clinical staff. The company is committed to enhancing the quality of life for its patients through comprehensive, round-the-clock care and ongoing mental health training.

DX Bako is a healthcare services company that specializes in diagnostic and therapeutic services primarily for podiatric physicians. The company offers a range of specialty laboratory testing, including anatomic pathology, nail DNA testing, and peripheral neuropathy immuno-histochemical testing. Additionally, DX Bako provides proprietary molecular genetic testing and office-dispensed therapeutics. Committed to advancing the field of podiatric dermatology, the company emphasizes education and research, striving to support healthcare providers with actionable information that enhances patient care.

Bako Integrated Physician Solutions is the premier provider of diagnostic and therapeutic services focusing on the skin, soft tissue and bone of the lower extremity. Their pathology team provides not just information, but also intelligence to enable better patient care.

Telesta Therapeutics is a Canadian biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative therapeutics aimed at addressing significant unmet medical needs, primarily in oncology. The company is focused on creating novel medicines that can transform the treatment landscape for serious diseases, including cancer and immune disorders. Its lead product, MCNA, has successfully completed a Phase III pivotal study for patients with non-muscle invasive bladder cancer who have not responded to initial treatment with bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application to the U.S. FDA in June 2015 and aims to provide MCNA to patients and healthcare providers pending approval. Ultimately, the company seeks to enhance the quality of life and extend survival for individuals affected by bladder cancer, one of the most prevalent cancers today.

Enclara Pharmacia, Inc. is a comprehensive provider of medications and clinical services tailored for the hospice and palliative care sectors. Founded in 1996 and based in Philadelphia, Pennsylvania, the company specializes in offering a direct-to-patient mail order pharmacy model alongside access to a network of retail pharmacies, including its automated fulfillment and institutional pharmacies. Enclara Pharmacia's services encompass hospice mail order pharmacy solutions, clinical support services, business intelligence tools, and educational resources designed to facilitate compliance with state regulations and enhance medication management. By focusing on operational efficiency and patient-centered care, the company aims to improve the quality of life for patients facing progressive illnesses and supports hospice providers across the United States. In October 2014, Enclara Pharmacia changed its name from excelleRx, Inc., and as of January 2020, it operates as a subsidiary of Eagle RX, Inc.

Kepro is a provider of technology-enabled services focused on care coordination and quality assurance for federal healthcare payers and self-funded organizations. The company specializes in a range of services, including case management, assessments, enrollment, pharmacy management, and absence management. Additionally, Kepro offers maternity management and independent medical reviews, aimed at enhancing healthcare quality and operational efficiency for its clients. The company also provides reporting and analytic services to support and improve client operations, ensuring better outcomes for individuals seeking to remain in their communities.

Enclara Pharmacia, Inc. is a comprehensive provider of medications and clinical services tailored for the hospice and palliative care sectors. Founded in 1996 and based in Philadelphia, Pennsylvania, the company specializes in offering a direct-to-patient mail order pharmacy model alongside access to a network of retail pharmacies, including its automated fulfillment and institutional pharmacies. Enclara Pharmacia's services encompass hospice mail order pharmacy solutions, clinical support services, business intelligence tools, and educational resources designed to facilitate compliance with state regulations and enhance medication management. By focusing on operational efficiency and patient-centered care, the company aims to improve the quality of life for patients facing progressive illnesses and supports hospice providers across the United States. In October 2014, Enclara Pharmacia changed its name from excelleRx, Inc., and as of January 2020, it operates as a subsidiary of Eagle RX, Inc.

Corindus designs, manufactures, and commercializes remote robotic systems for interventional procedures. The company's products include CorPath, which enables physicians to perform catheterization procedures from a remote location away from the radiation zone. The company was formerly known as Navicath, Ltd. Corindus was founded in 2002 and is based in Waltham, Massachusetts.